<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    When will there be news on fda approval
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        7/8/2024 08:24pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">The FDA approval news for Arcutis Biotherapeutics Inc. (ARQT) is expected on July 7, 2024, for the supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. This is a significant regulatory catalyst for the company, and the decision is eagerly awaited by investors.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:s,comeFrom:"AInvestShareLink",events:e,answerSource:i}],fetch:{},error:e,state:{sharePreviewModule:{loadJgySuccess:t,dialogRenderList:[{originAnswer:{input_media_info:[],bottom_reason:{chain_name:a,reason_msg:a,bottom_type:a,bottom_level:a},agent_id:a,output_media_info:[],task_id:a,source:i,execute_mode:u,param:"{\"trace_id\":\"20003020172044148047800000000905\",\"question\":\"When will there be news on fda approval\",\"user_id\":\"1801885132\",\"user_name\":\"\",\"input_type\":\"typewrite\",\"session_id\":\"c780f335a16eddb76a5454b28884b0bd\",\"source\":\"ths_wencai_international\"}",agent_info:[{info_type:"search",title:v,full_summary:"FDA has set a PDUFA target action date of July 07, 2024 Atopic dermatitis affects approximately 16.5 million adults and 9.6 million children in the United States sNDA supported by positive efficacy and safety data from the pivotal Phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials WESTLAKE VILLAGE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. Roflumilast cream is a once-daily, steroid-free, phosphodiesterase-4 (PDE4) inhibitor. The FDA assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of July 07, 2024. “Atopic dermatitis is a chronic and recurring inflammatory skin condition that requires therapy that is effective, tolerable, and suitable for long-term use by both adults and children. Due to its waxing and waning nature, long-term disease control is ideal for the patient versus cyclical treatment, which consists of starting and stopping treatment when skin is controlled and when it is not,” said Lawrence Eichenfield MD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego, professor of dermatology and pediatrics and vice-chair of the Department of Dermatology at UC San Diego School of Medicine, and study investigator. “In clinical t",summary:w,url:x,publish_time:"2023-11-29"}],answer_chain_name:"agent_common_v2\nagent-summary",come_from:a,text_answer:s,trace_id:k,cost:15642,question:d,input_type:y,session_id:l,first_return_cost:5915,transfer_question:d,start_time:z,remote_svc:"jgateway",slots:[{ner_types:[],ner_type:a,desc:"the financial instruments that user is looking for news about. Financial instruments include stocks, stock codes, funds, fund codes, ETFs, indexes, and cryptocurrencies. It only comes from entity recognition result \u003Centities\u003E, may be empty '', concatenated with ';' if multiple.",importance:"required",values:[A],name_en:B,clarify_text:a,extra_msg:{Arcutis:{word:"arqt",name:A,code:"ARQT.O",type:"stock",start_pos:[43]}},name:B,type:a,default_value:a,normalize_type:a,normalized:c},{ner_types:[],ner_type:a,desc:"Determine if the query is about a specific news event or news for a financial instrument. Output 'TRUE' for specific events, 'FALSE' for instrument news.",importance:"no",values:["True"],name_en:C,clarify_text:a,extra_msg:{},name:C,type:a,default_value:a,normalize_type:a,normalized:c}],intervene_result:[],answer_type:u,user_id:j,skill_name:D},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",base_info:{trace_id:k,session_id:l,user_id:j,question:d,source:i,raw_question:d,version:"3.3.3"},extra:{}},{answer_path:f,section:{id:g,info_texts:["Thinking"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},extra:{}},{answer_path:f,section:{id:g,info_texts:["Searching Web : Arcutis Biotherapeutics Inc. FDA approval process"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:E},extra:{}},{answer_path:f,section:{id:g,info_texts:["Searching Web : Arcutis Biotherapeutics Inc. FDA approval timeline"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:E},extra:{}},{answer_path:f,section:{id:g,info_texts:["Generating Answer"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},extra:{}},{answer_path:m,section:{id:F,info_texts:[],show_type:n,voice_txt:"The",text_answer:G,rich_text:G,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:m,section:{id:2000,info_texts:[],show_type:n,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:x,title:v,summary:w,index:1}],is_last:b},extra:{}},{answer_path:m,section:{id:F,info_texts:[],show_type:n,voice_txt:a,text_answer:H,rich_text:H,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:f,section:{id:g,info_texts:["Completed"],show_type:h,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:I,choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10001,info_texts:[],show_type:I,choice:[{display_text:o,query_text:o,trace_info:{item_id:"e18348b42c9365a2fa24bf4d7ccd75cb",item_type:p,item_name:o,rec_info:"0+320_351_21_130+0+0+20003020172044148047800000000905+e18348b42c9365a2fa24bf4d7ccd75cb+llm_generated+aimeTagOther+0+onLineLGBM+1"}},{display_text:q,query_text:q,trace_info:{item_id:"767f6e49a514d5e7711d2b16944e31d1",item_type:p,item_name:q,rec_info:"0+320_351_21_130+0+0+20003020172044148047800000000905+767f6e49a514d5e7711d2b16944e31d1+llm_generated+aimeTagOther+0+onLineLGBM+2"}},{display_text:r,query_text:r,trace_info:{item_id:"86c7772838d30528cc24a64f5e828a11",item_type:p,item_name:r,rec_info:"0+320_351_21_130+0+0+20003020172044148047800000000905+86c7772838d30528cc24a64f5e828a11+llm_generated+aimeTagOther+0+onLineLGBM+3"}}],result_page:{},tag_info_list:[],is_last:b},extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:"signal",choice:[],result_page:{},tag_info_list:[],is_last:b},extra:{action_name:D,link_ids:[],with_paid_index:c},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:e,docsData:[],quoteData:e},tplType:"question"},events:void 0,agentId:a,param:{trace_id:k,question:d,user_id:j,user_name:a,input_type:y,session_id:l,source:i}}],userId:j,userName:a,startTime:z,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:e,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:t,traceTableData:e,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fwhen-will-there-be-news-on-fda-approval-2fc06f\u002F",config:{_app:{basePath:J,assetsPath:J,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"When will there be news on fda approval",null,"progress\u002Fsearching_for",1000,"searching_for","ths_wencai_international","1801885132","20003020172044148047800000000905","c780f335a16eddb76a5454b28884b0bd","other\u002FopenAnswer","rich_text","What are the current regulatory requirements for FDA approval of new drugs?","llm_generated","What are the potential implications of recent regulatory changes or guidance documents on the timing of FDA approval for new drugs?","How long does it typically take for the FDA to review a new drug application (NDA)?","The FDA approval news for Arcutis Biotherapeutics Inc. (ARQT) is expected on July 7, 2024, for the supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6. This is a significant regulatory catalyst for the company, and the decision is eagerly awaited by investors.",0,"agent","FDA Accepts Arcutis' Supplemental New Drug Application ...","FDA Accepts Arcutis' Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children ...","https:\u002F\u002Fwww.arcutis.com\u002Ffda-accepts-arcutis-supplemental-new-drug-application-for-roflumilast-cream-0-15-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-down-to-age-6\u002F","typewrite",1720441480480,"Arcutis","instrument","news_event","search news","thinking",2001,"The FDA approval news for Arcutis Biotherapeutics Inc. (ARQT) is expected on July 7, 2024, for the supplemental new drug application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in adults and children down to age 6","[^1]. This is a significant regulatory catalyst for the company, and the decision is eagerly awaited by investors.","choice","\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>